NASDAQ-100 INDEX The NASDAQ-100 Index includes 100 of the largest domestic and international non-financial companies listed on The NASDAQ Stock Market based on market capitalization. The Index reflects companies across major industry groups including computer hardware and software, telecommunications, retail/wholesale trade and biotechnology. Last week, the...
Gilead Sciences , Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency...
Initiated a long - possible 10% to 14% upside short term - looking at $88 maybe higher GILD is getting net new committed business (orders) from outside the US market for Remdesivir will feel much better once GILD clears the red zone - a retest into that zone won't be a very good sign.
Just trying to get a picture of GILEAD and where its heading. Maybe it will be in Range here for a while ( near support line ) Maybe it should go down and touch MA 50 befor turning ? Maybe we are goinf down to hard support at couse 65 ? Maybe we just jump up from here ? I am waiting to find a reversal pattern. Yeah there are many ways to trade - what are...
The chart explains it all. the market keeps raising against all odds in the middle of this world pandemic, ignoring all data and indicators... Why shorting then? Buy the bottom of the tunnel sell at mid range before it gets to the danger zone and bounce back again key points; - price at the bottom of the tunnel - price riding the EMA 50 - good buying risk...
What is XBi? XBI provides exposure to one of the broadest portfolios among US biotech ETFs. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with...
Global debt out of control. How will all these companies who could barely manage their debt pre-Covid manage increased debt with higher borrowing costs and weakened consumer demand after Covid-19 lockdowns end? Remdesivir was per Dr. Fauci "highly significant if you look at time to recovery." Sorry folks but it looks like GILD moved the goal posts (changed the...
The GILD price fold into the inside pitchork channel on the long term. This signal a long term downtrend, which does not serve visionary long term investment. However, for the intermediate term analysis. GILD price follow channel patter as is in the second channel. Despite the extraordinary selling volume, the price found a strong support at 75$. GILD next TP...
GILD has seen positive price action YTD; due to combatting the COVID-19 with their drug Remdesivir. Yesterday on the news, the trial on humans which was set in China to prove the effectivity of the drug, apparently "failed". However... The price just took us to the lower part of the channel , meaning the Risk-Reward-Ratio is at a good stance. A close below...
Trade Plan for Gilead Sciences. Will look to enter at bottom of uptrend channel (75.3) , Stop Loss once uptrend broken (74). Target Price at 86. Potential Price at 96. Personally will take profit at resistances as insurance. Upside for Gilead: 1a) Possible treatment for Covid-19 (Remdesivir) 1b) Possible 2nd wave of virus 2) Possible FDA approval of Arthritis...
GILD is the leader on the treatment side of the game with its remdesivir asset. The market will likely react to every new development. But the chart is very constructive at this point. However, everything will depend on new data from trials now underway around the world.
Those who follow me know I have been bearish (and still am in the long term) since January. However looking at the IWM which has been a very good leading indicator of the market overall, the Gild news could have breathed a new lease of life to the market. Looking at the actions a few days before the GILD news we can see that the IWM was rejected twice and closed...
SUMMARY: Looking for a long entry on Gilead Sciences (GILD) after the gap up on news of a COVID treatment. HEADLINE: Looking for a Long Entry After the Gap Up TICKER: GILD STRATEGY USED: Silver Scalper Trend Confirmation = Range MA Entry Signal = Bull/Bear Power Exit Signal = Bull/Bear Power OR Range MA --- DESCRIPTION: 1. With this strategy we enter long on...
GILD shares will open in the $90 area, it would appear (on Thursday evening). The hints on Remdesivir results for COVID-19 treatment suggest a significant response among severe patients. Given that the world hangs in the balance, the stakes couldn't be higher. This stock will be the tail wagging the S&P for the next week.
This is not my typical type of setup, however the prospects of GILD look very inciting. GILD is currently working on a coronavirus vaccine and is the closest to having a FDA approved vaccine in the future. Any positive announcements could cause GILD to spike in price as coronavirus fears continue. On the weekly chart, there is clear bottoming price action...
NASDAQ:GILD $GILD - I Mean Come On! #SuperSimpleCharts